MTOR rs2536 — The miRNA Switch in the Longevity Pathway
The mTOR (mechanistic target of rapamycin) protein is the central command node for one of the most consequential decisions cells make: whether to grow or to clean house. When nutrients and growth signals are abundant, mTOR drives protein synthesis and cell proliferation. When mTOR is suppressed — by fasting, caloric restriction, or rapamycin — cells shift toward autophagy and stress resistance, the cellular programs most closely tied to longevity across every organism where this has been tested. rs2536 is a variant in the 3' untranslated region (3'UTR) of the MTOR gene that adjusts this setting through a post-transcriptional mechanism distinct from the promoter variant rs2295080.
The two MTOR variants in the GeneOps database regulate mTOR expression through different molecular mechanisms but converge on the same biology: lower mTOR activity means more autophagy, better protein quality control, and — based on the cancer and survival data — measurably better outcomes in contexts where mTOR overactivity drives disease.
The Mechanism
rs2536 sits in the 3' untranslated region of the MTOR gene — the portion of the mRNA that comes after the stop codon and is never translated into protein. The 3'UTR is not silent: it is the primary docking site for microRNAs (miRNAs), short RNA molecules that bind to the 3'UTR and suppress gene expression by either blocking translation or triggering mRNA degradation.
The rs2536 T>C substitution alters a binding site for microRNA-150 (miR-150) | a miRNA expressed broadly in immune, vascular, and epithelial tissues that normally suppresses several growth-promoting genes. The C allele creates a higher-affinity miR-150 binding site compared to the T allele. When miR-150 binds more strongly, it more efficiently suppresses MTOR mRNA translation — meaning C-allele carriers have lower MTOR protein levels in their tissues.
Direct expression analysis confirmed this | Functional variant of MTOR rs2536 and survival of Chinese gastric cancer patients. Int J Cancer, 2019: in 144 patients' adjacent normal gastric tissue samples, MTOR mRNA expression was measurably lower in TC/CC carriers than in TT homozygotes (p=0.043). This is the same functional gradient — TT > TC > CC in MTOR expression — seen with the rs2295080 promoter variant, achieved through a completely different molecular lever.
The Evidence
Cancer prognosis: The most functionally informative study examined 1,002 Chinese gastric cancer patients. The rs2536 C allele was independently associated with a 26% reduction in death risk | Functional variant of MTOR rs2536 and survival of Chinese gastric cancer patients. Int J Cancer, 2019 (HR 0.74, 95% CI 0.57–0.96, p=0.022). This survival benefit persisted after adjusting for tumor stage, age, and treatment. Functional follow-up showed that lower mTOR expression in TC/CC carriers correlated with reduced cancer cell proliferation, migration, and invasion in vitro.
Cancer susceptibility: Results are mixed and cancer-type-dependent. In a prostate cancer study of 1,004 Eastern Chinese cases and 1,051 controls, TC/CC genotypes were associated with increased prostate cancer risk | Polymorphisms in the mTOR gene and risk of sporadic prostate cancer in an Eastern Chinese population. PLOS One, 2013 (dominant model OR 1.42, 95% CI 1.13–1.78, p=0.003). In childhood acute lymphoblastic leukemia, the direction reversed: the TC genotype was associated with a significantly decreased leukemia risk (adjusted OR 0.67, 95% CI 0.46–0.96), with stronger protection in T-phenotype ALL (OR 0.29 for TC/CC combined). The opposing directions by cancer type mirror the same paradox seen with rs2295080 and leukemia — mTOR biology in hematological malignancies appears distinct from solid tumors.
Meta-analysis: A comprehensive pooled analysis of 18 Chinese studies (6,653 cases, 7,025 controls) found no significant overall association across all cancer types, but within the population-based control subgroup (3,252 cases, 3,368 controls), rs2536 showed a significant association in the dominant model (OR 1.20, 95% CI 1.01–1.42, p=0.038) and allele model (OR 1.17, 95% CI 1.04–1.32, p=0.012). The overall null result reflects heterogeneity across cancer types rather than true absence of effect.
The evidence base is almost entirely from Chinese populations. European and other ancestry data are sparse, warranting the moderate evidence rating.
Practical Actions
The actionable implications of rs2536 overlap substantially with those of rs2295080, since both variants regulate mTOR expression in the same direction. TT homozygotes have the highest mTOR expression of the three genotypes and benefit most from deliberate behavioral mTOR suppression: extended overnight fasting, periodic protein restriction, and regular endurance exercise (which activates AMPK, the natural antagonist of mTOR). TC carriers have intermediate mTOR activity and similar but lower-urgency considerations. CC carriers have the lowest mTOR expression and enjoy the most favorable cancer prognosis signal, though they may need to be deliberate about maintaining adequate protein intake to support muscle mass, since mTOR also drives anabolic signaling.
Regardless of genotype, mTOR activity is suppressed by: fasting (the most potent lever), leucine restriction, and exercise-induced AMPK activation. It is stimulated by: dietary protein (especially whey and BCAAs), insulin, and IGF-1. The rs2536 genotype tells you how aggressively you need to apply these tools given your constitutive mTOR expression level.
Interactions
rs2536 and rs2295080 are independent MTOR variants that regulate mTOR expression through different mechanisms (3'UTR miRNA binding vs. promoter transcription factor binding). Carriers of the protective allele at both sites (rs2536 C and rs2295080 G) would be expected to have the lowest overall MTOR expression. Neither variant has been studied in combination in a single cohort, but the additive biology is straightforward — both attenuate the same protein.
The broader PI3K-AKT-mTOR signaling axis involves upstream variants in PTEN, AKT1, and TSC1/TSC2 that modulate how strongly growth signals activate mTOR. Downstream, FOXO3 (rs2802292) operates in the same longevity network: AKT phosphorylates and inactivates FOXO3, so lower mTOR activity in rs2536 C carriers means less AKT-driven FOXO3 suppression, complementing the longevity biology of the FOXO3 G-allele.
All genotypes
Common wild-type genotype — no reduction in miR-150-mediated mTOR suppression
You have two copies of the T allele at rs2536, the most common genotype. The T allele at this 3'UTR site supports baseline MTOR expression without the additional microRNA-150-mediated suppression conferred by the C allele. This is the reference genotype in all the cancer studies reviewed, representing approximately 68% of people globally in study control populations. TT homozygotes have the highest constitutive MTOR expression among the three genotypes at this locus. In the gastric cancer survival study, TT carriers had the worst prognosis of the three groups; in the prostate cancer study, TT had the lowest susceptibility risk relative to TC/CC — illustrating how cancer-type context determines whether higher mTOR expression is harmful or beneficial in different tissue settings.
Two C alleles maximally enhance miR-150 binding — lowest MTOR expression and strongest cancer prognosis signal
You have two copies of the C allele at rs2536. The C allele creates a high-affinity binding site for microRNA-150, which suppresses MTOR mRNA translation. CC homozygotes have the lowest MTOR tissue expression of the three genotypes — confirmed by direct mRNA measurement in normal tissue adjacent to gastric tumors (p=0.043 lower than TT). This genotype is uncommon — roughly 0.7% in Chinese control populations (CC homozygosity for a minor allele present at ~8.7% frequency). In the gastric cancer survival data, CC carriers together with TC carriers had a 26% lower death risk (HR 0.74) compared to TT. The ALL data also shows strong protective effects in T-phenotype leukemia (OR 0.29 for combined TC/CC).
One C allele partially increases miR-150 binding — intermediate mTOR expression with partial protective effect
You have one T allele and one C allele at rs2536. The C allele creates a higher-affinity binding site for microRNA-150, which suppresses MTOR mRNA translation. Having one copy places you at intermediate mTOR expression levels compared to TT and CC homozygotes. In the gastric cancer survival study of 1,002 patients, TC carriers had better survival outcomes than TT homozygotes, with the effect reflecting lower MTOR tissue expression confirmed by direct RNA measurement. In the childhood leukemia study, the TC genotype was associated with meaningfully reduced ALL risk (OR 0.67). About 28% of people in Chinese control populations carry this genotype.